The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo

Arthritis and Rheumatism

Volumn 63, Issue 9, 2011, Pages 2744-2754

  Kukita, Akiko ^a   Kukita, Toshio ^b   Nagata, Kengo ^b   Teramachi, Junpei ^b   Li, Yin Ji ^b   Yoshida, Hiroki ^a   Miyamoto, Hiroshi ^a   Gay, Steffen ^c   Pessler, Frank ^d,e   Shobuike, Takeo ^a  

^a SAGA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CALCEIN; CATHEPSIN K; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FBI 1; TRANSCRIPTION FACTOR LRF; TRANSCRIPTION FACTOR OCZF; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE HISTOMORPHOMETRY; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DENSITY; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; RANK LIGAND; RATS; TRANSCRIPTION FACTORS;

EID: 80052331060     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30455     Document Type: Article

References (45)

1. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-602.
2. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
3. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9. (Pubitemid 27507987)
4. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S,. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2523-30.
5. Boyle WJ, Simonet WS, Lacey DL,. Osteoclast differentiation and activation. Nature 2003; 423: 337-42. (Pubitemid 40852708)
6. Takayanagi H,. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292-304. (Pubitemid 46480961)
7. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443-8.
8. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R,. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997; 3: 1285-9. (Pubitemid 27508833)
9. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901. (Pubitemid 35460788)
10. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004; 50: 794-804. (Pubitemid 38326179)
11. 3 receptor. Blood 2001; 98: 3290-300.
12. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM,. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13: 199-212.
13. Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell 2009; 17: 527-40.
14. Kelly KF, Daniel JM,. POZ for effectPOZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006; 16: 578-87. (Pubitemid 44636217)
15. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 1997; 94: 10762-7. (Pubitemid 27430808)
16. Kukita A, Kukita T, Ouchida M, Maeda H, Yatsuki H, Kohashi O,. Osteoclast-derived zinc finger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis. Blood 1999; 94: 1987-97. (Pubitemid 29430415)
17. Davies JM, Hawe N, Kabarowski J, Huang QH, Zhu J, Brand NJ, et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene 1999; 18: 365-75. (Pubitemid 29060612)
18. Pessler F, Pendergrast PS, Hernandez N,. Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Mol Cell Biol 1997; 17: 3786-98. (Pubitemid 27281853)
19. Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, et al. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 2007; 316: 860-6. (Pubitemid 46764272)
20. Kukita T, Kukita A, Nagata K, Maeda H, Kurisu K, Watanabe T, et al. Novel cell-surface Ag expressed on rat osteoclasts regulating the function of the calcitonin receptor. J Immunol 1994; 153: 5265-73. (Pubitemid 24356159)
21. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004; 279: 45969-79. (Pubitemid 39491590)
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
23. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005; 433: 278-85.
24. Watanabe T, Kukita T, Kukita A, Wada N, Toh K, Nagata K, et al. Direct stimulation of osteoclastogenesis by MIP-1α: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J Endocrinol 2004; 180: 193-201. (Pubitemid 38180771)
25. Kukita A, Kukita T, Hata K, Kurisu K, Kohashi O,. Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells. Bone Miner 1993; 23: 113-27.
26. Nagase Y, Iwasawa M, Akiyama T, Kadono Y, Nakamura M, Oshima Y, et al. Anti-apoptotic molecule Bcl-2 regulates the differentiation, activation, and survival of both osteoblasts and osteoclasts. J Biol Chem 2009; 284: 36659-69.
27. Lee DK, Kang JE, Park HJ, Kim MH, Yim TH, Kim JM, et al. FBI-1 enhances transcription of the nuclear factor-κB (NF-κB)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-κB. J Biol Chem 2005; 280: 27783-91.
28. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2 -C T method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
29. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114: 475-84. (Pubitemid 39572097)
30. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001; 155: 157-66. (Pubitemid 34286216)
31. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
32. Mizoguchi T, Muto A, Udagawa N, Arai A, Yamashita T, Hosoya A, et al. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol 2009; 184: 541-54.
33. Ogasawara T, Katagiri M, Yamamoto A, Hoshi K, Takato T, Nakamura K, et al. Osteoclast differentiation by RANKL requires NF-κB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6). J Bone Miner Res 2004; 19: 1128-36. (Pubitemid 41110565)
34. Okahashi N, Murase Y, Koseki T, Sato T, Yamato K, Nishihara T,. Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1). J Cell Biochem 2001; 80: 339-45. (Pubitemid 32141488)
35. Pang M, Martinez AF, Fernandez I, Balkan W, Troen BR,. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene 2007; 403: 151-8. (Pubitemid 47488713)
36. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259-69. (Pubitemid 30395733)
37. Laudes M, Bilkovski R, Oberhauser F, Droste A, Gomolka M, Leeser U, et al. Transcription factor FBI-1 acts as a dual regulator in adipogenesis by coordinated regulation of cyclin-A and E2F-4. J Mol Med 2008; 86: 597-608.
38. Laudes M, Christodoulides C, Sewter C, Rochford JJ, Considine RV, Sethi JK, et al. Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis. J Biol Chem 2004; 279: 11711-8. (Pubitemid 38401675)
39. Choi WI, Jeon BN, Yun CO, Kim PH, Kim SE, Choi KY, et al. Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1. J Biol Chem 2009; 284: 12633-44.
40. Sankar U, Patel K, Rosol TJ, Ostrowski MC,. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. J Bone Miner Res 2004; 19: 1339-48. (Pubitemid 41094376)
41. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV,. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 2008; 118: 2088-97. (Pubitemid 351872328)
42. Tanaka S, Wakeyama H, Akiyama T, Takahashi K, Amano H, Nakayama KI, et al. Regulation of osteoclast apoptosis by Bcl-2 family protein Bim and Caspase-3. Adv Exp Med Biol 2010; 658: 111-6.
43. Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI, et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 2003; 22: 6653-64. (Pubitemid 38009611)
44. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O,. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003; 101: 3451-9. (Pubitemid 36868944)
45. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. J Immunol 2005; 175: 5809-16. (Pubitemid 41508065)